Be the first person to write a business review for Intercell AG

Intercell USA (formerly Iomai) is developing needle-free alternatives to boost your immune system using a transcutaneous method, which delivers vaccines to cells found on the outer layers of the skin. It has a handful of product candidates in development, all in patch form, aimed at preventing seasonal flu and travelers' diarrhea (caused by E. coli, for instance). One of its patches is being funded under a contract from the US Department of Health and Human Services to aid in the treatment of pandemic flu. In 2008 the company was acquired by Austria-based vaccine maker Intercell AG.

Intercytex Limited company is developing cell-based treatments for skin and hair regeneration. Its ICX-TRC product candidate is injected just beneath the scalp to encourage new hair follicles to form. If the candidate wins approval in the US, Intercytex has lined up Bosley Medical Institute, a firm that manages hair transplant clinics across the US, to help distribute its regeneration product. Another product candidate, SHEF-1, could treat age-related macular degeneration. Its ICX-RHY launched in the UK in 2008 under the name Valvelta, as a cosmetic facial rejuvenation product injected transdermally to smoothe out wrinkles.

InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

Isotechnika Pharma may have isolated a new drug to combat organ rejection. Lead drug candidate voclosporin could replace cyclosporine as the immunosuppressant of choice for organ transplant recipients and patients with autoimmune conditions. Studies indicate it is more effective and has fewer side effects than cyclosporine. Isotechnika is testing the drug for kidney transplant recipients and psoriasis. Minority shareholder Paladin Labs has signed on to develop and market the drug in certain markets. Its Isotechnika Diagnostics division sells "breathalyzer" tests to diagnose H. pylori infections, which cause chronic gastritis and ulcers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.